IOHEXOL INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Iohexol Injection Market Size and Forecast – 2025 to 2032

The Global Iohexol Injection Market is estimated to be valued at USD 1.71 Bn in 2025 and is expected to reach USD 3.03 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032. This growth is driven by increased demand for contrast agents in diagnostic imaging and rising prevalence of chronic diseases requiring advanced imaging techniques. The expanding healthcare infrastructure and technological advancements in imaging modalities further support the robust market expansion over the forecast period.

Key Takeaways of the Global Iohexol Injection Market

• In terms of application, Computed Tomography (CT) Scans (Body/organ imaging) lead the Iohexol injection market, holding an estimated share of 30.2% in 2025.
• Within the dosage forms segment, injection is expected to dominate, contributing the largest share of 57.3% in the global Iohexol injection market in 2025.
• Among the different strengths of Iohexol injections, the 140 mg iodine/mL strength is expected to hold the highest market share, accounting for 23.2% in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.2% in 2025.

Market Overview

A notable trend in the Iohexol injection market is the growing emphasis on developing low-osmolar, non-ionic contrast agents to improve patient safety and reduce adverse reactions. Additionally, increasing adoption of minimally invasive diagnostic procedures and growing awareness among healthcare professionals about the benefits of high-quality contrast agents are fueling market growth. Strategic collaborations between pharmaceutical companies and healthcare providers are also enhancing product accessibility, leading to wider acceptance and usage of Iohexol injections globally.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Iohexol Injection Market Insights, By Application - Computed Tomography (CT) Scans

Body/organ imaging) Leads Due to Its Superior Contrast and Enhanced Imaging Quality

In terms of application, Computed Tomography (CT) Scans (Body/organ imaging) are estimated to dominate the Iohexol injection market, accounting for the largest share by a significant margin with 30.2% in 2025. The primary factor driving this dominance is the widespread use of CT imaging in diagnosing a broad spectrum of medical conditions due to its high-resolution visualization of body organs and tissues. Iohexol serves as a non-ionic, low-osmolar contrast agent that enhances the clarity of CT images, enabling more accurate detection and characterization of abnormalities.

The growing number of diagnostic imaging procedures globally, especially CT scans, plays a critical role in boosting demand for Iohexol injections. CT scans are essential in emergency and routine clinical settings for detecting cancers, cardiovascular diseases, and neurological conditions, all of which require high-quality contrast agents to improve image contrast. The safety profile of Iohexol, combined with its effectiveness in vascular and tissue imaging, makes it highly preferred among radiologists for enhancing CT scan results.

Iohexol Injection Market Insights, By Dosage Forms - Injections Dominate as the Preferred Dosage Form Due to Their Ability to Deliver Drugs Directly into the Bloodstream

Within the dosage forms segment, injections overwhelmingly contribute the largest share to the global Iohexol injection market with an estimated share of 57.3% in 2025. The injection form is favored predominantly due to its ability to deliver the contrast agent directly into the bloodstream, facilitating immediate and effective imaging enhancement. This direct intravenous administration ensures rapid circulation of Iohexol to target areas, enabling high-quality imaging outcomes essential for accurate diagnosis.

The preference for injections over oral solutions lies also in the pharmacokinetic properties of contrast media. Injected Iohexol displays faster distribution and more predictable contrast enhancement compared to oral counterparts, which require digestion and absorption, resulting in variable imaging results. Injection administration allows precise control over dosage and timing, critical factors in dynamic imaging procedures such as angiography and CT scans, where timing the peak contrast effect is vital.

Iohexol Injection Market Insights, By Strength - 140 mg Iodine/mL Concentration Dominates Due to Its Ideal Balance Between Providing High-Quality Contrast for Clear Imaging and Maintaining Patient Safety

Among the various available strengths of Iohexol injections, the 140 mg iodine/mL concentration is expected to hold the highest market share with 23.2% in 2025. This preferred strength is largely influenced by the balance it offers between effective contrast enhancement and patient safety, making it suitable for a wide range of diagnostic imaging indications.

Lower concentrations like 140 mg iodine/mL are often used because they provide sufficient radiopacity to improve visualization without exposing patients to higher iodine loads that could elevate the risk of adverse effects, particularly in vulnerable populations with compromised renal function or allergies. This strength allows physicians to tailor contrast doses carefully, ensuring diagnostic efficacy while mitigating potential nephrotoxicity or allergic reactions, which are critical considerations in clinical practice.

Regional Insights

To learn more about this report, Download Free Sample

North America Iohexol Injection Market Analysis and Trends

North America’s dominance in the global Iohexol injection market with an estimated share of 38.3% in 2025 is primarily driven by the region’s well-established healthcare infrastructure and high adoption of advanced diagnostic imaging technologies. The presence of a robust healthcare ecosystem, coupled with favorable government policies promoting early diagnosis and personalized medicine, enhances market penetration. Additionally, stringent regulatory frameworks ensure the quality and safety of Iohexol injections, boosting healthcare providers' confidence in these products.

Key industry players such as GE Healthcare, Bracco Diagnostics Inc., and Bayer AG maintain strong operations and innovation centers in North America, contributing substantially to market leadership through continuous product development and strategic partnerships with healthcare institutions. Moreover, North America’s extensive trade networks facilitate the efficient distribution of Iohexol-based contrast agents across the U.S. and Canada, strengthening market reach.

Asia Pacific Iohexol Injection Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the global Iohexol injection market with a share of 24.2% in 2025, fueled by increasing healthcare expenditure, the rising prevalence of chronic diseases requiring diagnostic imaging, and expanding medical infrastructure. Emerging economies such as China and India are investing heavily in healthcare modernization, supported by government initiatives to enhance diagnostic capabilities in urban and rural settings.

For example, Farbe Firma is an Indian manufacturer of various pharmaceutical products, including contrast agents. Its Iohexol injection is used in radiological procedures like angiography and CT scans. The company primarily operates in India and Africa, providing high-quality contrast agents to medical institutions.

The burgeoning middle-class population and increasing health awareness further drive demand. Local and international companies, including Shenzhen Salubris Pharmaceuticals and GE Healthcare, are capitalizing on this growth by establishing manufacturing units and forming joint ventures to improve supply chains.

Global Iohexol Injection Market Outlook for Key Countries

U.S. Iohexol Injection Market Trends

The U.S. iohexol injection market leads the global landscape with advanced medical imaging adoption and significant R&D investments. Leading companies like GE Healthcare and Bayer AG dominate through cutting-edge Iohexol formulations and strong distribution frameworks. The emphasis on early disease detection and routine screening protocols ensures consistent demand for contrast media, reinforcing the U.S. position as a pivotal market in diagnostic radiology.

For example, the National Cancer Institute (NCI) has funded various initiatives to support early cancer detection, many of which rely on advanced imaging technologies. Programs such as the National Lung Screening Trial have contributed to the growing use of CT scans for detecting lung cancer in its early stages, which necessitates the use of contrast agents like Iohexol to enhance imaging clarity. Such initiatives have fostered consistent demand for contrast media in the U.S.

Germany Iohexol Injection Market Trends

Germany continues to lead Europe’s iohexol injection market, driven by its highly developed healthcare system and patient-centric policies. Germany’s active radiology and cardiology sectors provide a stable demand base for Iohexol injections, supported by continuous innovation and clinical trials within the country.

Germany’s healthcare system, regulated by the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds), ensures that diagnostic imaging procedures, including those requiring contrast agents, are well-supported through comprehensive reimbursement schemes. This support fosters continued use of Iohexol injections in hospitals and diagnostic centers, ensuring its accessibility and adoption in clinical settings.

China Iohexol Injection Market Trends

China’s iohexol injection market experiences rapid expansion supported by government healthcare reforms aimed at improving diagnostic services nationwide. Increasing hospital upgrades and a growing pool of trained radiologists fuel the consumption of Iohexol injections. Companies such as Sinomed Pharmaceutical and GE Healthcare are significant contributors, focusing on localized production and cost-effective solutions to meet China’s diverse healthcare needs.

For example, Jiangsu Hengrui Medicine is one of the leading pharmaceutical manufacturers in China, specializing in innovative medicines and medical devices. The company produces Iohexol Injection, which is used in diagnostic imaging for CT and angiographic procedures. It serves a vast network across China and has a growing international presence.

India Iohexol Injection Market Trends

India’s iohexol injection market growth is propelled by increasing healthcare accessibility and government programs targeting rural health improvement. The presence of both domestic manufacturers like Hetero Labs and multinational firms allows for competitive pricing and wider distribution. Investments in diagnostic imaging infrastructure and rising awareness about non-invasive diagnostic procedures significantly contribute to the growing adoption of Iohexol-based products.

For example, Intelicure Lifescience is an Indian pharmaceutical company specializing in contrast media and diagnostic agents. It manufactures Iohexol Injection, which is used for a wide range of imaging procedures, including CT and angiography. The company mainly operates within India and Asia Pacific.

End User Feedback and Unmet Needs in the Global Iohexol Injection Market

• End users of Iohexol injections, primarily healthcare providers such as hospitals and diagnostic imaging centers, have consistently highlighted the critical role of contrast agents in enhancing diagnostic accuracy. Positive feedback from end users often emphasizes the high performance of Iohexol in complex imaging procedures, such as CT scans and angiography. For instance, a radiology department in a leading hospital reported significant improvements in diagnostic precision for coronary artery imaging, noting that Iohexol's low toxicity and high contrast resolution helped reduce procedural complications. This positive user experience underscores the agent's value in providing clear, high-quality imaging, particularly in cardiovascular and neuroimaging diagnostics. Furthermore, the easy integration of Iohexol with advanced imaging technologies has been lauded for supporting smoother workflows in diagnostic settings, enhancing throughput without compromising patient safety.
• However, end-users also voice several concerns regarding operational limitations and product accessibility. A commonly cited issue is the high cost of Iohexol injections, especially for smaller healthcare facilities or in developing regions, where financial constraints limit access to premium contrast agents. Additionally, the standardization of Iohexol formulations across different brands has led to challenges in customization, with some users reporting that the available concentrations or volumes do not always align with the specific needs of certain diagnostic procedures, resulting in inefficient resource utilization. Another concern is the lack of local availability in certain geographies, where supply chain disruptions often lead to delays in procurement. These unmet needs suggest technological gaps, such as the need for more affordable and customizable options, and improvements in distribution networks. Addressing these challenges could open up growth opportunities by expanding market reach, increasing customer retention through tailored offerings, and fostering innovation in contrast media formulations, ultimately leading to better patient outcomes and more efficient healthcare delivery.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In January 2025, GE HealthCare, a global leader in medical technologies, announced a USD 138 million investment to expand its manufacturing facility in Carrigtohill, Cork, Ireland. The new 3,000 m² facility will increase production capacity by 25 million additional patient doses of contrast media per year by 2027. This expansion is driven by the growing global demand for iodine-based contrast media, including Iohexol injection, fueled by aging populations and rising chronic diseases. The investment aims to support the increasing need for diagnostic imaging and enhance supply capacity worldwide.
• In June 2025, Beijing Beilu Pharmaceutical Co., Ltd. received marketing authorization for its Iohexol Injection from the Hungarian National Institute of Pharmacy and Nutrition (OGYÉl). This approval follows its earlier authorization in the Netherlands and marks a significant step in Beilu Pharma’s expansion into European markets. The approval strengthens the company’s competitive edge in contrast media products and supports its global growth, particularly in South America, Africa, and Asia Pacific. Beilu has also seen notable success in the export of contrast agent formulations and APIs.
• In December 2023, GE Healthcare reported a COVID-19-related disruption in Iohexol manufacturing, leading to a global shortage of iodinated contrast agents, severely affecting urological practices. This shortage underscored the need for alternative contrast agents and imaging procedures. The article reviews alternatives like older iodinated agents (ioxaglate, diatrizoate), gadolinium-based agents (e.g., Gadavist), and other methods like air contrast pyelography and contrast-enhanced ultrasound.
• In February 2020, Glenmark Pharmaceuticals recalled specific batches of Iohexol 350mg/ml and Iohexol 300mg/ml solutions for injection as a precautionary measure. The affected batches, PL 25258/0247 and PL 25258/0246, were recalled following safety concerns, as per the Medicines and Healthcare products Regulatory Agency (MHRA) notification issued on 6 February 2020. The company has provided contact details for medical and stock-related inquiries.

Top Strategies Followed by Global Iohexol injection Market Players

• Leading players in the global Iohexol injection market, such as GE Healthcare, Bracco Diagnostic Inc., and Guerbet LLC, excel through strong investments in R&D to enhance product performance and meet clinical needs. These companies focus on innovation in imaging technologies and contrast agents, with strategic acquisitions and partnerships further expanding their market presence. Their efforts ensure the development of high-quality, efficient diagnostic solutions, solidifying their leadership in the Iohexol injection sector.
  • For example, GE HealthCare and Jiangsu Hengrui Medicine are prime examples of established players. GE HealthCare offers Omnipaque, a widely used Iohexol injection product, continuously improving imaging quality for CT scans and angiography. Jiangsu Hengrui Medicine manufactures Iohexol injection products for diagnostic imaging and continues to innovate, ensuring their presence in global markets. Both companies collaborate with hospitals, diagnostic centers, and OEMs to strengthen their market position.

• Mid-level players in the Indian Iohexol injection market, such as Intelico Pharmaceuticals, Maya Biotech, Amber LifeSciences, and Rege Imaging, focus on providing high-quality contrast agents at competitive prices to meet the needs of price-sensitive healthcare facilities. These companies offer a range of Iohexol formulations, including 350 mg/mL concentrations in 50 mL and 100 mL vials, catering to various diagnostic imaging requirements. By enhancing production efficiencies and forming strategic collaborations with technology providers, contract manufacturers, and regional distributors, they ensure the availability of affordable Iohexol solutions without compromising clinical efficacy or safety.
  • For example, Onko Ilac Sanayi ve Ticaret A.S. and Swasthya Healthcare Pvt. Ltd. are examples of mid-level players. Swasthya Healthcare manufactures affordable Iohexol Injection products for the Indian and Middle Eastern markets, catering to healthcare facilities looking for cost-effective contrast agents. Onko Ilac focuses on providing affordable diagnostic imaging solutions, ensuring the availability of high-quality contrast agents at competitive prices through strategic partnerships with regional distributors.

• Small-scale players in the Iohexol injection market, such as Farbe Firma and Intelicure Lifescience, focus on niche segments by developing specialized products with technological innovation. Intelicure Lifescience improves Iohexol injection stability and patient-friendly administration for smaller clinics, while Farbe Firma targets regional needs in India, offering Iohexol injections tailored for local markets. Both companies form local alliances with distributors to overcome entry barriers and gain visibility in targeted regions, leveraging agility and technology to differentiate themselves in a competitive market.
  • For example, Farbe Firma and Intelicure Lifescience are examples of small-scale players. Intelicure Lifescience focuses on developing Iohexol injections with enhanced drug stability and patient-friendly administration methods, catering to smaller clinics. Farbe Firma, operating primarily in India, develops Iohexol injections tailored for specific regional needs and collaborates with local distributors to increase market presence. These companies use technological innovation to create competitive differentiation in localized markets.

Market Report Scope

Iohexol Injection Market Report Coverage

Iohexol Injection Market Dynamics

To learn more about this report, Download Free Sample

Iohexol injection Market Driver - Increasing Demand for Advanced Diagnostic Imaging Techniques

The rising adoption of sophisticated diagnostic imaging technologies is a significant driver propelling the demand for Iohexol injections globally. As healthcare providers increasingly rely on precise and rapid imaging to enhance patient outcomes, contrast agents like Iohexol play a critical role in improving the clarity and accuracy of radiographic images such as CT scans and angiographies. Advancements in imaging modalities, including high-resolution and 3D imaging, necessitate the use of reliable and safe contrast media that can effectively highlight anatomical structures and pathological conditions. Furthermore, the expanding prevalence of chronic diseases such as cardiovascular disorders, cancer, and neurological conditions calls for frequent and detailed diagnostic evaluations, further escalating the use of contrast agents like Iohexol.

On July 24, 2025, GE HealthCare, a global leader in medical technology, launched the Definium Pace Select ET, a floor-mounted digital X-ray system designed to enhance imaging quality and workflow efficiency in high-demand environments. The system automates repetitive tasks and reduces physical strain on technologists by leveraging AI for accurate patient positioning and consistent image quality across various clinical conditions. This innovation addresses the growing demand for X-ray exams, the high burnout rates among radiology technologists, and staffing challenges in healthcare.

Iohexol injection Market Opportunity: Development of Next-Generation Contrast Agents with Improved Safety Profiles

The global Iohexol injection market is poised to benefit significantly from advancements in the development of next-generation contrast agents that prioritize enhanced safety profiles. Currently, while Iohexol remains a widely used non-ionic, low-osmolar contrast medium, concerns surrounding adverse reactions such as allergic responses, nephrotoxicity, and other side effects continue to influence the adoption rates, particularly among high-risk patient groups. This creates a substantial opportunity for pharmaceutical companies and research institutions to innovate and introduce contrast agents that minimize these risks without compromising imaging efficacy. The development of safer contrast media can address unmet clinical needs, especially among vulnerable populations, including patients with renal impairments, elderly individuals, and those with prior hypersensitivity. Moreover, advancements in molecular structures and formulation techniques hold the potential to reduce osmolality further and improve biodegradability, thereby enhancing patient tolerability and broadening clinical applications.

In February 2025, Lantheus Medical Imaging, a global leader in medical imaging diagnostics, announced successful Phase III clinical trial results for its novel manganese-based MRI contrast agent. This agent could serve as a potential alternative to gadolinium-based agents for patients with renal impairment and addresses environmental concerns.

Analyst Opinion (Expert Opinion)

• The global Iohexol injection market is experiencing robust growth, driven by a combination of technological advancements in diagnostic imaging and increasing demand for non-invasive, accurate diagnostic tools. Key factors such as the growing adoption of CT scans and angiography procedures, particularly in aging populations with chronic conditions, are propelling market demand. The low-osmolarity properties of Iohexol offer significant safety advantages over older contrast agents, further fueling its widespread use. Additionally, regulatory support from organizations like the USFDA and EMA has streamlined its availability, ensuring higher safety standards and expanding access globally. The rising demand for diagnostic imaging, alongside advancements in AI-powered diagnostics, offers significant growth opportunities.
• However, the market also faces challenges, including supply chain disruptions and the need for constant regulatory compliance in various regions. Despite these, opportunities lie in the expanding healthcare infrastructure in emerging markets and the development of next-generation contrast agents. Notable industry events such as the RSNA Annual Meeting and European Congress of Radiology have contributed to knowledge sharing and policy formation, influencing market dynamics through technological showcases and regulatory updates. Real-world examples include partnerships between GE Healthcare and local governments to enhance imaging capabilities in underserved regions, positioning the market for significant growth in the coming years.

Market Segmentation

• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Computed Tomography (CT) Scans (Body/organ imaging)
  • Angiography and Angiocardiography
  • Myelography
  • Arthrography
  • Other Applications (e.g., Urography, Hysterosalpingography, ERCP)
• Dosage Forms Insights (Revenue, USD Bn, 2020 - 2032)
  • Injection
  • Oral Solution
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 140 mg iodine/mL
  • 180 mg iodine/mL
  • 240 mg iodine/mL
  • 300 mg iodine/mL
  • 350 mg iodine/mL
  • 9 mg iodine/mL
  • 12 mg iodine/mL
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Intrathecal
  • Intra-arterial
  • Intravenous
  • Oral
  • Rectal
  • Intraarticular
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adults
  • Pediatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Specialty Clinics
  • Diagnostic Centers
  • Imaging Centers
  • Ambulatory Surgical Centers
  • Others (Research and Academic Institutes)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • GE HealthCare
  • Torso Healthcare
  • MANUS AKTTEVA BIOPHARMA LLP
  • Farbe Firma
  • Swasthya Healthcare Pvt. Ltd.
  • Intelicure Lifescience
  • Onko Ilac Sanayi ve Ticaret A.S
  • Grupo Juste
  • Jiangsu Hengrui Medicine

Sources

Primary Research Interviews

• Industry Stakeholders List
  • Radiologists
  • Medical Imaging Technologists
• End Users List
  • Healthcare Providers (Hospitals, Diagnostic Imaging Centers)
  • Pharmaceutical Manufacturers

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Institute for Health and Care Excellence (NICE)
• Centers for Medicare and Medicaid Services (CMS)

Trade Publications

• Radiology Today
• Diagnostic Imaging
• Medical Imaging Technology
• Journal of Clinical Imaging Science

Academic Journals

• Journal of Radiology
• Journal of Medical Imaging
• The British Journal of Radiology
• European Radiology

Reputable Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• The Times of India

Industry Associations

• Radiological Society of North America (RSNA)
• European Society of Radiology (ESR)
• American College of Radiology (ACR)
• International Society for Magnetic Resonance in Medicine (ISMRM)

Public Domain Resources

• National Institutes of Health (NIH)
• U.S. National Library of Medicine
• National Cancer Institute (NCI)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years